Omeros Corporation
$ 11.55
1.49%
26 Feb - close price
- Market Cap 806,847,000 USD
- Current Price $ 11.55
- High / Low $ 11.58 / 11.28
- Stock P/E N/A
- Book Value -3.15
- EPS -1.99
- Next Earning Report 2026-03-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.32 %
- ROE -5.76 %
- 52 Week High 17.65
- 52 Week Low 2.95
About
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.
Analyst Target Price
$38.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-14 | 2025-05-13 | 2025-03-31 | 2024-11-07 | 2024-08-07 | 2024-05-15 | 2024-03-26 | 2023-11-09 | 2023-08-09 | 2023-05-09 | 2023-03-13 |
| Reported EPS | -0.34 | -0.43 | -0.5408 | -0.55 | -0.64 | -0.97 | -0.63 | -0.15 | -0.6 | -0.59 | -0.54 | 2.05 |
| Estimated EPS | -0.45 | -0.46 | -0.58 | -0.71 | -0.7 | -1.14 | -0.58 | -0.55 | -0.62 | -0.57 | -0.56 | -0.57 |
| Surprise | 0.11 | 0.03 | 0.0392 | 0.16 | 0.06 | 0.17 | -0.05 | 0.4 | 0.02 | -0.02 | 0.02 | 2.62 |
| Surprise Percentage | 24.4444% | 6.5217% | 6.7586% | 22.5352% | 8.5714% | 14.9123% | -8.6207% | 72.7273% | 3.2258% | -3.5088% | 3.5714% | 459.6491% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-30 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.55 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OMER
2026-02-22 00:52:14
Omeros Corporation (NASDAQ:OMER) has received a consensus "Moderate Buy" rating from five brokerages, with an average one-year price target of $40.33. While some analysts, like HC Wainwright, have significantly increased their price targets and maintained "buy" ratings, others, including Wall Street Zen and Weiss Ratings, have issued or reaffirmed "sell" ratings, indicating mixed views. Insider David J. Borges recently sold 30,000 shares, and institutional investors collectively hold nearly half of the stock.
2026-02-18 05:27:02
Omeros (OMER) has completed an initial study in nonhuman primates for its OncotoX-AML cancer therapeutic platform, which targets acute myeloid leukemia. The study showed that a single course of OncotoX-AML treatment led to a significant, selective, and reversible reduction of myeloid progenitor cells by up to 99% while being well-tolerated with no significant safety signals. This development is promising as current AML treatments are often limited by substantial side effects.
2026-02-17 13:27:26
Omeros Corporation announced the successful completion of an initial nonhuman primate study for its OncotoX-AML™ cancer therapeutic platform, targeting acute myeloid leukemia (AML). The study showed that a single treatment course led to a significant, selective, and reversible reduction in myeloid progenitor cells by up to 99 percent, with no major safety signals. Omeros plans to initiate IND-enabling studies to advance OncotoX-AML™ to clinical trials, aiming for a first-in-human trial in late 2027.
2026-02-11 18:27:26
Omeros (OMER) stock surged in premarket trading following FDA approval for its drug, narsoplimab, the first treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This approval is seen as a significant long-term growth driver, with analysts predicting substantial revenue and potential for Omeros to become a major pharmaceutical company, despite concerns about trial sizes.
2026-02-09 18:11:04
Omeros Corporation has commenced the commercial launch of its FDA-approved drug, YARTEMLEA®, in the U.S. for transplant-associated thrombotic microangiopathy (TA-TMA). This milestone, along with a significant licensing deal with Novo Nordisk for $2.1 billion, positions Omeros as a commercial-stage entity with bolstered financial resources. The company anticipates an EMA decision for YARTEMLEA® mid-year and plans to release its Q4/full-year 2025 financial results between March 3 and April 2.
2026-02-09 17:28:37
Omeros Corporation has launched its first FDA-approved therapy, YARTEMLEA®, in the U.S. for transplant-associated thrombotic microangiopathy (TA-TMA), marking its transition into a commercial-stage company. Concurrently, Omeros secured a significant licensing deal with Novo Nordisk for its investigational drug, Zaltenibart, including an upfront payment of $240 million, which is expected to cover debt and operations for over a year. The company aims for positive cash flow by 2027 and anticipates a European marketing authorization decision for YARTEMLEA® around mid-year.
